Characterization of PI (breast cancer cell special peptide) in MDA-MB-231 breast cancer cells and its potential therapeutic applications

Gao,Change; Hong,Min; Geng,Jiwei; Zhou,Huahua; Dong,Jian

doi:10.3892/ijo.2015.3140

Characterization of PI (breast cancer cell special peptide) in MDA-MB-231 breast cancer cells and its potential therapeutic applications

Authors:
- Change Gao
- Min Hong
- Jiwei Geng
- Huahua Zhou
- Jian Dong
View Affiliations

Affiliations: Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China, Medical Oncology, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650018, P.R. China
Published online on: August 31, 2015 https://doi.org/10.3892/ijo.2015.3140
Pages: 1371-1378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene therapy is one of the most important aspects of molecular targeted therapeutic approaches for tumors. A small molecule targeting carrier plays an important role in this process. PI, a new peptide found in our phage library, has been specifically suggested, combined with the human triple-negative breast cancer cell line MDA-MB‑231, and may be developed as a targeting/individualization therapy strategy to be applied in breast cancer research. In this study, we further investigated whether this peptide could carry exogenous protein to the target cells by forming a fusion peptide. PI-GST and PI-TK were cloned into plasmids and used for expression studies, analyses of PI-mediated protein delivery efficiency, and to investigations into the effect of PI on thymidine kinase/ganciclovir-mediated cytotoxicity. Biodistribution profiles were also investigated in vivo. The results showed the PI fusion protein was expressed correctly in vitro, and could carry GST into the target cells. Under certain conditions, PI-TK sensitizes cells to ganciclovir more efficiently than TK. In vivo there was a trend for increased inhibition of tumor growth with PI-TK when ganciclovir was present. Therefore, our results suggest the potential of PI as a new specific target carrier in breast cancer therapy.

View Figures

View References

1	Aguas F, Martins A, Gomes TP, de Sousa M and Silva DP; Portuguese Menopause Society and Portuguese Gynaecology Society. Prophylaxis approach to a-symptomatic post-menopausal women: Breast cancer. Maturitas. 52(Suppl 1): S23–S31. 2005. View Article : Google Scholar : PubMed/NCBI
2	Dumitrescu RG and Cotarla I: Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med. 9:208–221. 2005. View Article : Google Scholar : PubMed/NCBI
3	O'Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, Swarbrick A and Oakes SR: Therapeutic targets in triple negative breast cancer. J Clin Pathol. 66:530–542. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hurley J, Reis IM, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R and Pegram MD: The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: Retrospective analysis of 144 patients. Breast Cancer Res Treat. 138:783–794. 2013. View Article : Google Scholar : PubMed/NCBI
5	Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, et al: Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med. 54:913–921. 2013. View Article : Google Scholar : PubMed/NCBI
6	Rodler E, Korde L and Gralow J: Current treatment options in triple negative breast cancer. Breast Dis. 32:99–122. 2010.
7	De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S: Treatment of triple negative breast cancer (TNBC): Current options and future perspectives. Cancer Treat Rev. 36(Suppl 3): S80–S86. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, et al: Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 27:2705–2711. 2009. View Article : Google Scholar : PubMed/NCBI
9	Helleday T, Bryant HE and Schultz N: Poly (ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle. 4:1176–1178. 2005. View Article : Google Scholar : PubMed/NCBI
10	Koren E and Torchilin VP: Cell-penetrating peptides: Breaking through to the other side. Trends Mol Med. 18:385–393. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ryu JS, Kuna M and Raucher D: Penetrating the cell membrane, thermal targeting and novel anticancer drugs: The development of thermally targeted, elastin-like polypeptide cancer therapeutics. Ther Deliv. 5:429–445. 2014. View Article : Google Scholar : PubMed/NCBI
12	Dong J, Liu W, Jiang A, Zhang K and Chen M: A novel peptide, selected from phage display library of random peptides, can efficiently target into human breast cancer cell. Chin Sci Bull. 53:860–867. 2008. View Article : Google Scholar
13	Zadeh G, Qian B, Okhowat A, Sabha N, Kontos CD and Guha A: Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol. 164:467–476. 2004. View Article : Google Scholar : PubMed/NCBI
14	De Palma M, Venneri MA and Naldini L: In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther. 14:1193–1206. 2003. View Article : Google Scholar : PubMed/NCBI
15	Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell. 55:1179–1188. 1988. View Article : Google Scholar : PubMed/NCBI
16	Frankel AD and Pabo CO: Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 55:1189–1193. 1988. View Article : Google Scholar : PubMed/NCBI
17	Du B, Han H, Wang Z, Kuang L, Wang L, Yu L, Wu M, Zhou Z and Qian M: targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide. Mol Cancer Res. 8:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
18	Li ZJ, Wu WKK, Ng SSM, Yu L, Li HT, Wong CC, Wu YC, Zhang L, Ren SX, Sun XG, et al: A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J Control Release. 148:292–302. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Yin G, Yan D, Wei Y, Ma C, Huang Z, Liao X, Yao Y, Chen X and Hao B: In vitro screening of ovarian tumor specific peptides from a phage display peptide library. Biotechnol Lett. 33:1729–1735. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yu Z, Wu J, Wu S, Jia P, Tong Y, Wu X and Wang Y: A recombinant cell-permeable p53 fusion protein is selectively stabilized under hypoxia and inhibits tumor cell growth. Cancer Lett. 279:101–107. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hu M, Wang J, Chen P and Reilly RM: HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Bioconjug Chem. 17:1280–1287. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bitler BG, Menzl I, Huerta CL, Sands B, Knowlton W, Chang A and Schroeder JA: Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res. 15:100–109. 2009. View Article : Google Scholar : PubMed/NCBI
23	Massodi I, Bidwell GL III, Davis A, Tausend A, Credit K, Flessner M and Raucher D: Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin Exp Metastasis. 26:251–260. 2009. View Article : Google Scholar : PubMed/NCBI
24	Bidwell GL III, Davis AN and Raucher D: Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release. 135:2–10. 2009. View Article : Google Scholar
25	Harada H, Hiraoka M and Kizaka-Kondoh S: Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 62:2013–2018. 2002.PubMed/NCBI
26	Takada Y, Singh S and Aggarwal BB: Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem. 279:15096–15104. 2004. View Article : Google Scholar : PubMed/NCBI
27	Tan M, Lan K-H, Yao J, Lu CH, Sun M, Neal CL, Lu J and Yu D: Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 66:3764–3772. 2006. View Article : Google Scholar : PubMed/NCBI
28	Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, et al: Discovery of orally active nonpeptide vitro-nectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem. 43:22–26. 2000. View Article : Google Scholar : PubMed/NCBI
29	Zhao H, Wang J-C, Sun Q-S, Luo C-L and Zhang Q: RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target. 17:10–18. 2009. View Article : Google Scholar
30	Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T and Kruse CA: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther. 9:87–95. 2002. View Article : Google Scholar : PubMed/NCBI